LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

66%

34%

338 / 374 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. nov 2025, 15:29 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

28. nov 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28. nov 2025, 19:59 UTC

Market Talk

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

28. nov 2025, 19:47 UTC

Market Talk

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

28. nov 2025, 18:16 UTC

Market Talk

Global Equities Roundup: Market Talk

28. nov 2025, 18:16 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28. nov 2025, 18:08 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

28. nov 2025, 18:08 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28. nov 2025, 17:48 UTC

Market Talk

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

28. nov 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28. nov 2025, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

28. nov 2025, 15:51 UTC

Market Talk

Canada Household Spending Edges Lower -- Market Talk

28. nov 2025, 15:33 UTC

Market Talk

Crude Futures Gain as U.S. Market Reopens -- Market Talk

28. nov 2025, 15:21 UTC

Market Talk

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

28. nov 2025, 15:13 UTC

Market Talk

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

28. nov 2025, 15:11 UTC

Market Talk

Global Equities Roundup: Market Talk

28. nov 2025, 15:11 UTC

Market Talk

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

28. nov 2025, 14:51 UTC

Market Talk

Canada GDP Report Masks Fragile State of Economy -- Market Talk

28. nov 2025, 14:41 UTC

Market Talk

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

28. nov 2025, 14:37 UTC

Market Talk

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

28. nov 2025, 14:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. nov 2025, 14:33 UTC

Market Talk

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

28. nov 2025, 14:20 UTC

Market Talk

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

28. nov 2025, 14:10 UTC

Market Talk

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

28. nov 2025, 13:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. nov 2025, 13:39 UTC

Market Talk

Canada Trade Data Could Face Larger-Than-Normal Revisions -- Market Talk

28. nov 2025, 13:36 UTC

Market Talk

Canada's Economy Expands More Than Expected -- Market Talk

28. nov 2025, 13:29 UTC

Market Talk

CME Outage Sowing Chaos Across Markets, Trade Nations Says -- Market Talk

28. nov 2025, 13:27 UTC

Market Talk

Russia-Ukraine Peace Efforts to Have Little Impact on Oil Fundamentals -- Market Talk

28. nov 2025, 13:19 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

338 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.